Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (5.990.515 €): Ein hochdimensionaler Ansatz zur Abschwächung immunmetabolischer Ursachen von Herz-Kreislauf-Krankheits-Depressionsmultimorbiditäten Hor01.01.2020 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Ein hochdimensionaler Ansatz zur Abschwächung immunmetabolischer Ursachen von Herz-Kreislauf-Krankheits-Depressionsmultimorbiditäten
Depression is a common and serious comorbidity of cardiovascular disease (CVD) affecting one in three patients, among which women earlier and more frequently. Depression increases the risk for CVD development, acute events and mortality by >2 fold, independently of traditional risk factors, and constitutes an enormous socioeconomic burden in terms of morbidity, mortality and healthcare costs. Still, the patients at risk, disease trajectories and causative mechanisms involved remain unknown. TO_AITION addresses the hypothesis that immune-metabolic dysregulation, occurring as a result of genetic, lifestyle and environmental risk factors ‘training’ innate immunity, drives low grade systemic inflammation leading to the development of CVD-depression comorbidity. It integrates basic (cell models, immune-metabolic mechanisms, myeloid cell reprogramming), preclinical (animal models, CRISPR genome editing) and clinical (longitudinal cohorts with comprehensive existing data) research, in order to characterise immune-metabolic mechanisms driving CVD-depression comorbidity. Both hypothesis and data-driven strategies will be employed to address causality, focusing on genetic, epigenetic, transcriptional, metabolic and other disturbances leading to the development of comorbidity. Drug-drug interactions and their effects on causative mechanisms and disease trajectories will also be determined. Pathways identified will be evaluated in cell-based and animal models to prove their causal role and obtain mechanistic insight. Finally, new risk models will be developed, and relevant regulatory, cost-effectiveness and feasibility issues addressed. Effective patient-oriented awareness actions, dissemination, exploitation and management activities are also provisioned. TO_AITION will therefore rationally change our current understanding of the causative mechanisms driving CVD-depression comorbidity, unravelling patients’ complexity and improving their diagnosis, monitoring and management.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Exelixis Diacheirisi Erevnas Kai Epikoinonia ΕΕ | 249.813 € |
| Genoway | 249.921 € |
| 879.344 € | |
| 351.775 € | |
| PIRKANMAA HOSPITAL DISTRICT | 526.400 € |
| 661.000 € | |
| RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG | 330.000 € |
| 204.925 € | |
| Stichting Amsterdam UMC | 429.683 € |
| 440.000 € | |
| UNIVERSITE DE GENEVE | 483.750 € |
| Universitair Medisch Centrum Utrecht | 473.750 € |
| Universiteit Van Amsterdam | 458.155 € |
| Universytet Medyczny w Lodzi. | 252.000 € |
Quelle: https://cordis.europa.eu/project/id/848146
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Exelixis Diacheirisi Erevnas Kai Epikoinonia EE - EU-Förderung (5.990.515 €): Ein hochdimensionaler Ansatz zur Abschwächung immunmetabolischer Ursachen von Herz-Kreislauf-Krankheits-Depressionsmultimorbiditäten"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
